- 2003 Master of Science in Engineering Biology, Umeå University, Umeå.
- 2008 PhD in Biotechnology, Royal Institute of Technology, Stockholm.
- 2009-2013 Postdoc, Karolinska Institutet, Stockholm.
Prostate cancer is the most common type of cancer in men and is the most frequent cause of death from cancer in Sweden. Prostate cancer is efficiently found through prostate-specific antigen screening and biopsy procedures but as it is significantly age-related, with few elderly men benefiting from surgery, the main problem is not to treat. Instead, it is how to identify whom to treat to avoid overtreatment and how to best monitor patients, which are put on observation rather than surgery.
To remedy the situation my research aims to make use of prognostic information in tumor tissues, collected after surgery. Subsequently, this will be applied on biopsy material, a prerequisite to have clinical impact, as the goal is to reduce the proportion of treated age-related indolent cancers. In addition, as the tumor grows, tumor DNA fragments are continuously being released into the circulation offering means for efficient disease monitoring. This has not been thoroughly investigated for prostate cancer and I aim to evaluate the prognostic potential of total systemic tumor load before surgery and its sensitivity to monitor disease progression by repetitive measurements of prostate-specific antigen and circulating tumor DNA after surgery.
Current research grants
Astra Zeneca/Karolinska Institutet
Circulating tumor DNA as a personalized biomarker for treatment predication and disease monitoring in prostate and breast cancer.
Total sum: 9 200 000 SEK (2013-2016)
Supervision (as co-supervisor)
- Amanda Seipel (Lars Egevad main supervisor).
- Daniela Danneman (Lars Egevad main supervisor).
- Anna Kristiansen (Lars Egevad main supervisor).
- Claes Lindh (Lars Egevad main supervisor).